Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMH5 | ISIN: US6033802058 | Ticker: 4MNA
Tradegate
17.11.26 | 17:16
1,970 Euro
-1,30 % -0,026
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
MINERVA NEUROSCIENCES INC Chart 1 Jahr
5-Tage-Chart
MINERVA NEUROSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,9782,00218.11.
1,9472,04418.11.

Aktuelle News zur MINERVA NEUROSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMinerva Neurosciences, Inc. - 8-K, Current Report-
06.11.Minerva Neurosciences, Inc. - 10-Q, Quarterly Report-
06.11.Minerva Neurosciences GAAP EPS of -$0.19 misses by $0.012
06.11.Minerva Neurosciences reports Q3 results, Phase 3 data due 2H 20271
MINERVA NEUROSCIENCES Aktie jetzt für 0€ handeln
06.11.Minerva Neurosciences, Inc: Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business Updates2
06.11.Minerva Neurosciences, Inc. - 8-K, Current Report-
29.10.Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London329BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...
► Artikel lesen
28.10.Minerva Neurosciences, Inc: Minerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of Schizophrenia476BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...
► Artikel lesen
28.08.Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences887BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...
► Artikel lesen
14.08.Jefferies upgrades Minerva Neurosciences stock rating on regulatory pathway5
07.08.Minerva Neurosciences, Inc. - 10-Q, Quarterly Report2
07.08.Minerva Neurosciences, Inc. - 8-K, Current Report1
07.08.Minerva Neurosciences, Inc: Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates1.176Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established...
► Artikel lesen
04.06.Minerva Neurosciences, Inc. - 8-K, Current Report2
01.06.Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs502Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)...
► Artikel lesen
27.05.Minerva Neurosciences, Inc. - 8-K, Current Report3
18.05.Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference486BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous...
► Artikel lesen
05.05.Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates1.363Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug-drug...
► Artikel lesen
02.04.Minerva Neurosciences, Inc: Minerva Announces Leadership Transition693Jim O'Connor joins as Chief Business Officer and General CounselBURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company...
► Artikel lesen
31.03.Minerva Neurosciences, Inc: Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia685Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected...
► Artikel lesen
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1